AdipoPharma Targets Root Cause Of Diabetes With First ‘Adipeutic’ Drug Candidate
Executive Summary
Emerging Company Profile: The French biotech is developing a constrained peptide that targets an interaction in body fat tissue in the hopes of treating type 2 diabetes.
You may also be interested in...
GSK Makes ADC Pipeline Comeback With Mersana Deal
The UK major has teamed up with the US biotech to develop the latter’s HER-2 targeted antibody-drug conjugate, a couple of years after the approval of Blenrep, in what is becoming an increasingly competitive space.
Novo Touts Diabetes R&D As Ozempic Faces Lilly Challenger
The Danish major highlighted a spate of diabetes pipeline updates during its second quarter earnings as blockbuster drug Ozempic grappled with a new rival in the shape of Lilly’s Mounjaro.
Merck KGaA’s Bavencio And Mavenclad Growth Steal Show During Q2 Earnings
Sky-high sales growth of the German major’s Bavencio and Mavenclad caught the eye of some observers as the firm continues to advance these drugs in new disease settings to unlock their full potential.